Key Highlights•
448-patient Phase 2 clinical trial in osteoarthritis expected to commence in 2H 2019
Costs of trial substantially funded by NHMRC; no cash contribution from Cynata
Cynata to supply Cymerus MSCs to facilitate the trial
This trial will be one of the largest MSC trials ever run, representing a breakthrough achievement for Cynata and showcasing its capacity to produce MSCs at scale
•Cynata retains full commercial rights to the use of Cymerus MSCs in osteoarthritis, representing a market opportunity forecast to be worth US$11.6 billion globally by 2025
•Osteoarthritis becomes the third Phase 2 indication for Cynata, highlighting demand for the company’s Cymerus MSCs in multiple indications
•Trial will take place in Sydney and Tasmania, and will be managed by a world-class clinical team led by Professor David Hunter of the University of Sydney
Fair Value Please, page-277
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $46.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 26.0¢ | $22.52K | 86.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34500 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 8292 | 2 |
View Market Depth
| Last trade - 15.25pm 19/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |